A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Worldwide, Dose-Ranging Clinical Trial with a Proof-of-Concept Lead Cohort to Evaluate the Safety, Tolerability, and Efficacy of MK-8457 + MTX in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy [Et randomiseret, dobbeltblindt, placebokontrolleret, verdensomspaendende, dosisbestemmende klinisk multicenterforsog i fase II med parallelle grupper med en bevis-for-effekt ledende kohorte, der vurderer sikkerhed, tolerance og effekt af MK-8457 + MTX til patienter med aktiv kronisk leddegigt pa trods af behandling med methotrexate].

Discontinued
Phase of Trial: Phase II

Latest Information Update: 15 Mar 2017

At a glance

  • Drugs MK 8457 (Primary) ; Methotrexate
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms AM2
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Aug 2016 This trial was completed in Germany (End Date:2 Sep 2013).
    • 26 Mar 2014 According to the ClinicalTrials.gov record, status changed from recruiting to discontinued.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top